Closely held AiM Medical Robotics has announced a collaboration agreement with Siemens Healthineers (FSE: SHL) for the implementation of an interface enabling AiM’s robotic platform to operate with MRI systems from Siemens Healthineers.
According to AiM, the interface supports the integration of AiM’s compact, MRI-compatible robotic stereotactic neurosurgery system and associated workflow with Siemens Healthineers’ MAGNETOM MRI scanners. This interface-based integration represents an important step toward coordinated robot–MRI operation and provides a foundation for future collaboration opportunities. Building on this technical compatibility, AiM sees the potential to further explore deeper levels of integration aimed at advancing precision and efficiency in image-guided neurosurgical interventions.
Under the new agreement, AiM’s system will connect with the MRI scanners of Siemens Healthineers, ranging from 1.5T and 3T to 0.55T MRI systems including the recently launched MAGNETOM Free.XL, which promises to substantially boost the accessibility of MRI-guided interventions. This software interface enables data exchange and collaborative functionality between the robotic platform and the MRI system. This integration is a key enabler of real-time, in-bore neurosurgical precision, elevating image-guided therapies to new clinical and workflow standards.
In a statement, Gregory Fischer, PhD, founder and CEO of AiM, commented, “The opportunity to collaborate with a global technology leader like Siemens Healthineers further validates AiM’s technology and expands the ecosystem needed to bring next-generation precision robotics to image-guided operating suites worldwide. This collaboration accelerates our roadmap toward clinical deployment and reinforces AiM’s mission to make MRI-guided neurosurgery faster, safer, and more accessible.”
The AiM collaboration with Siemens is poised to benefit from several interventional MRI (iMRI) tailwinds.
In September 2025, Cook Medical, a large family-owned medical device company known for its focus on minimally invasive treatment options, and Siemens Healthineers announced a strategic commercial partnership aimed at creating ‘iMRI Suites.’
“MRI in the interventional suite has always been a concept with tremendous clinical potential, but it has also faced significant barriers. At Siemens Healthineers, we are committed to breaking those barriers to unlock new clinical opportunities and advance patient care. Together with Cook Medical, we’re leading the way into a new era where iMRI becomes a precise radiation-free standard of care,” Andreas Schneck, head of Magnetic Resonance at Siemens Healthineers, said in a statement.
Meanwhile, Profound Medical (NASDAQ: PROF; TSX: PRN) and Siemens Healthineers are waiting for FDA clearance to commercialize a new MRI-guided prostate therapy solution which combines Profound’s TULSA-PRO system and consumables with Siemens Healthineers’ Magnetom Free.Max MR scanner. On its Q1-2026 investor call, Profound’s CEO, Arun Menawat, PhD, said that “if all goes well, TULSA will get FDA clearance for integration with the new interventional MR by yearend, and we believe that will meaningfully contribute to our growth in 2027.”
But the AI-powered, MRI-guided robotic TULSA Procedure is already gaining commercial traction, with Profound’s TULSA-PRO system being used with a variety of traditional 1.5T and 3T MR scanners manufactured by Siemens, Philips and GE. And earlier this year, The Johns Hopkins Hospital treated its first non-clinical-trial prostate cancer patient using the company’s TULSA-PRO system. The milestone not only marked the official launch of the TULSA Procedure at one of the world’s most influential centers for prostate cancer innovation, but also coincided with the opening of Johns Hopkins Medicine’s new iMRI suite—signaling the continued evolution of MRI from diagnostic imaging-only to a real-time therapeutic platform.
